Effect of Isoniazid Resistance on Treatment Outcome Among People With Pulmonary Tuberculosis in Korea Authors: Jong Min Lee, Hyung Woo Kim, Eung Gu Lee, Yeonhee Park, Sung Soo Jung, Jin Woo Kim, Jee Youn Oh, Heayon Lee, Seung Hoon Kim, Sun-Hyung Kim, Jiwon Lyu, Sun Jung Kwon, Yun-Jeong Jeong, Dojin Kim, Hyeon-Kyoung Koo, Ganghee Chae, Sun Young Kyung, Sung Soon Lee, Jae Seuk Park, Ju Sang Kim, Jinsoo Min Published: 2025 ABSTRACT BackgroundIsoniazid resistance is the most common type of ant-tuberculosis drug resistance, which is often neglected in clinical practice. This study aimed to evaluate the impact of isoniazid mono-resistant tuberculosis (Hr-TB) on the treatment outcomes of people with pulmonary tuberculosis.MethodsPeople with pulmonary tuberculosis were enrolled from the Korea Tuberculosis Cohort (KTBC) registry and the multicenter prospective cohort study of pulmonary tuberculosis (COSMOTB). Isoniazid resistance was confirmed using drug susceptibility test results. The primary outcome was an unfavorable outcome, which defined as comprising death, failure, loss-to-follow-up, still-on-treatment, and not-evaluated. Logistic regression analysis was conducted to evaluate effect of isoniazid resistance on treatment outcomes. We also compared 2-month sputum negative culture conversion rate and incidence of adverse events between Hr-TB and drug-susceptible tuberculosis.ResultsFrom the KTBC and COSMOTB databases, 10,482 and 758 participants were included, respectively. Compared to drug-susceptible tuberculosis, Hr-TB had higher rates of unfavorable outcome in the KTBC (45.8% vs. 37.0%, P < 0.001) and COSMOTB (31.5% vs. 17.9%, P = 0.014). Multivariable logistic regression analysis showed significant association between isoniazid resistance and unfavorable outcome in the KTBC (adjusted odds ratio [aOR], 1.43; 95% confidence interval [CI], 1.24–1.65) and in the COSMOTB (aOR, 1.98; 95% CI, 1.02–3.85). Additional analyses on COSMOTB data showed that Hr-TB had more serious adverse drug reactions, while 2-month sputum culture conversion rates did not differ significantly.ConclusionIsoniazid resistance is significantly associated with unfavorable clinical outcomes. INTRODUCTION The introduction of the Xpert MTB/RIF assay has significantly improved the speed and accuracy of diagnosing tuberculosis (TB) and detecting rifampin (RIF, R) resistance, enabling more prompt isolation of the patients and their optimal treatment.1234 However, since this test is unable to detect isoniazid (INH) resistance, isoniazid mono-resistant tuberculosis (Hr-TB) was often neglected and resulted in delayed diagnosis compared to RIF-resistant TB.5 This is particularly concerning given that INH resistance is the most common type of drug-resistant TB6 and its incidence is still increasing.7 Previous meta-analyses have shown that patients with Hr-TB tend to have worse outcomes compared to those with drug-susceptible tuberculosis (DS-TB).89 In 2018, the World Health Organization (WHO) recommended the addition of levofloxacin (Lfx) to the standard regimen of RIF, ethambutol (EMB, E), and pyrazinamide (PZA, Z) for the Hr-TB treatment.10 However, this recommendation was based on observational studies, with no supporting evidence from randomized controlled trials.1112 Moreover, real-world assessments of the REZ-Lfx regimen are incomplete, and its efficacy remains uncertain. Despite its weak evidence, substituting INH with Lfx in the treatment of Hr-TB is expected to improve outcomes, as fluoroquinolones are well known for their effective anti-TB activity by inhibiting mycobacterial DNA replication131415 and essential in the treatment of multidrug-resistant TB.16 Since most of the previous studies on Hr-TB treatment outcomes were conducted before the updates of the WHO guidelines in 2018, their findings might not reflect the current standard of care and changes of TB epidemiology. The Republic of Korea (South Korea) is an intermediate TB-burden country with increasing TB incidence rate among elderly population. This issue is particularly relevant as older people with TB in Korea exhibit higher rates of INH resistance compared to younger individuals,17 compounding the challenges of TB management in this elderly population. The presence of chronic comorbidities in older people and prolonged duration of Hr-TB treatment could increase risk of adverse drug reactions, often resulting in poor treatment outcomes. In this study, we hypothesized that the treatment outcome of Hr-TB has been improved after the updated treatment recommendations. Using two prospective nationwide databases of the Korean population, we assessed the effect of INH resistance on treatment outcomes among people with pulmonary TB, initially analyzing the Korean Tuberculosis Cohort (KTBC) registry and validating the results using the Cohort Study of Pulmonary Tuberculosis (COSMOTB) database. METHODS Study design and setting We designed a cohort study using two prospective nationwide databases on pulmonary TB in the Republic of Korea, the KTBC registry and COSMOTB database. Korea still falls in the category of intermediate-TB burden country, with a high rate of TB incidence when compared with other high-income countries.18 In this study, we first analyzed data from the KTBC, collected from hospitals nationwide participating in the Public-Private Mix (PPM) TB control project, with data obtained at two distinct time points: at treatment initiation and upon completion. To further validate our findings, we subsequently conducted an analysis using data from the COSMOTB. The COSMOTB dataset comprised patients from a representative subset of PPM hospitals selected from diverse geographic regions, with data systematically collected at regular intervals throughout anti-TB treatment.19 This approach enabled a more comprehensive and robust evaluation of treatment outcomes. KTBC The KTBC is a prospective observational cohort registry database of notified people with active TB in Korea from July 2018 to December 2020.20 The KTBC registry was established using data from PPM project, which was expanded nationwide in 2011 for TB surveillance and control.2122 For this database, every TB patient notified from the first to the tenth day of each month was consecutively enrolled. Approximately 79.4% of newly notified TB patients in Korea were treated at the PPM project-participating hospitals in 2020. The KTBC data were established to support the development of future evidence-based plan and policy, aligned with the goals of the advanced national TB elimination program. COSMOTB The COSMOTB is a prospective observational study conducted in 18 university-affiliated hospitals in Korea.23 The registration for the study was carried out from June 2019 to November 2021. Participants who were 19 years or older and had pulmonary TB were enrolled. The goal of COSMOTB study was to explore the clinical characteristics of pulmonary TB patients and confirm the possible risk factors of the unfavorable outcomes after TB treatment. Registered patients were regularly followed up for 24 months from the beginning of their anti-TB treatment, and the epidemiologic, socioeconomic, and clinical information regarding their diseases were recorded. Study participants The pulmonary TB patients registered in the KTBC and the COSMOTB database were enrolled, and the culture-based drug susceptibility testing confirmed their resistance status to anti-TB medications. DS-TB was defined when Mycobacterium tuberculosis strain was susceptible to INH, RIF, EMB, and PZA. Hr-TB was defined when resistance to INH was identified. The exclusion criteria were participants with only extrapulmonary TB or inactive TB, those with resistance to other anti-TB drugs, and those without drug susceptibility test results. The phenotypic drug susceptibility test was performed in a supranational reference laboratory (Korean Institute of Tuberculosis, Osong, Korea) or in other commercial reference laboratories. The workflows and references of the critical concentrations for anti-TB drug resistance were consistent among all reference laboratories. The culture-based drug susceptibility of M. tuberculosis complex isolates was determined using an absolute concentration method with Lowenstein-Jensen medium, as recommended by the WHO. Anti-TB drugs used and their critical concentrations for resistance were as follows: INH, 0.2 μg/mL; RIF, 40 μg/mL; EMB, 2.0 μg/mL. PZA susceptibility was determined using the pyrazinamidase test. Study outcomes All participants were followed up until the end of their anti-TB treatment. The primary outcome was unfavorable outcome from both KTBC registry and COSMOTB database, which was defined as comprising death, failure, loss-to-follow-up, still-on-treatment, and not-evaluated. The term ‘still-on-treatment’ was defined when the patient’s anti-TB treatment exceeded 1 year and was included as one of the unfavorable outcome definitions for our study. Other treatment outcomes were defined according to the WHO guideline.24 The secondary outcomes were sputum negative culture conversion at 2-month and incidence of severe adverse events and adverse drug reactions during anti-TB treatment. Sputum test results and adverse events were periodically monitored, and related data were stored in the COSMOTB database. Sputum studies were conducted at each clinical visit to identify negative culture conversion. Negative conversion was defined as two consecutive negative sputum cultures taken at least 7 days apart, while a positive result in either solid or liquid media was considered a positive culture. Individuals unable to produce sputum were categorized as culture negative. A questionnaire was used to collect information on the occurrence of adverse events, which were graded according to the Common Terminology Criteria for Adverse Events, version 5.0. The association between drugs and adverse events was assessed using the WHO-Uppsala Monitoring Centre causality categories. All data were subsequently re-checked by researchers during the data collection and analysis process. Data collection Basic clinical information of participants was collected: factors such as sex, age, body mass index (BMI), nationality, comorbidities, initial TB-related symptoms, prior TB history, sputum acid-fast bacilli smear results, chest radiographic findings, and existence of extra-pulmonary TB were used in the analysis. The initial severity of TB was classified based on chest radiographic findings and sputum smear results, reflecting the extent of pulmonary involvement and bacterial burden. Patients were categorized as having mild disease if they had no cavitary lesions on chest radiography and their sputum smear test was negative. Severe disease was defined as the presence of either a cavitary lesion on chest radiography or a positive sputum smear result. A positive sputum smear was defined as a smear grade of 1+ or higher according to the standard acid-fast bacilli smear grading system. Statistical analysis All categorical variables were expressed as numbers and percentages, and continuous variables were shown as means and standard deviations. Comparison of baseline characteristics between groups were described using Pearson’s chi-square tests for categorical variables and the independent t-test for continuous variables. For the evaluation of association between INH resistance and the clinical outcome, univariable logistic regression analysis was performed. Subsequently, variables with P value < 0.20 were selected for the multivariable logistic regression analysis. To evaluate the robustness of the primary outcome, the sensitivity analysis was conducted using redefined unfavorable outcome, which only included death, failure, still-on-treatment, and loss-to-follow-up, excluding cases classified as “not evaluate.” Further multivariable analyses were conducted to assess the effects of INH resistance on this redefined unfavorable outcome. The time to negative sputum culture conversion was compared between DS-TB and Hr-TB groups with the Kaplan-Meier method and their differences were analyzed using the log-rank test. All analysis were two-sided, and the statistical significance was set at P value < 0.05. Statistical analyses were conducted using SPSS for Windows ver. 28.0 (IBM Corp., Armonk, NY, USA). Ethics statement This study was approved by Institutional Review Board (IRB) of The Catholic University of Korea (IRB No. C19ONDI0458) and performed accordance with the Declaration of Helsinki. All hospitals participated in the registry obtained approval form their IRBs and all participants provided written informed consent to participate the cohort study of pulmonary tuberculosis (COSMOTB). RESULTS From 26,401 participants registered in the KTBC database, total of 10,482 patients with pulmonary TB were included in the analysis. Likewise, among 1,204 pulmonary TB patients registered in the COSMOTB database, 758 patients were included in the analysis (Fig. 1). Patient enrollment flow chart of KTBC registry (A) and COSMOTB (B). KTBC = Korean Tuberculosis Cohort, COSMOTB = Cohort Study of Pulmonary Tuberculosis, TB = tuberculosis, DS-TB = drug-susceptible tuberculosis, Hr-TB = isoniazid mono-resistant tuberculosis. The baseline clinical characteristics were compared between patients with Hr-TB and DS-TB from KTBC and COSMOTB database (Table 1). In the KTBC analysis, the proportion of patients with foreign nationality and prior TB history were significantly higher in the Hr-TB group. In contrast, among COSMOTB patients, foreign nationality, and diabetes were identified as factors showing significant difference between the groups. When comparing the rate of unfavorable outcome, both KTBC (45.8% vs. 37.0%, P < 0.001) and COSMOTB (31.5% vs. 17.9%, P = 0.014) populations exhibited higher rates in the Hr-TB group. The proportion of still-on-treatment, which is a component of the unfavorable outcome, was significantly higher in Hr-TB group than DS-TB group, in both KTBC (19.6% vs. 11.6%, P < 0.001) and COSMOTB (13.0% vs. 5.5%, P = 0.038). Table 1Baseline characteristics of patients with isoniazid mono-resistant tuberculosis and drug-susceptible tuberculosis enrolled from the KTBC registry and the COSMOTBVariablesKTBCCOSMOTBHr-TB (n = 906)DS-TB (n = 9,576)Total (N = 10,482)P valueHr-TB (n = 54)DS-TB (n = 704)Total (N = 758)P valueSex, male575 (63.5)6,037 (63.0)6,612 (63.1)0.80138 (70.4)443 (62.9)481 (63.5)0.274Age ≥ 65 yr448 (49.4)4,771 (49.8)5,219 (49.8)0.82929 (53.7)312 (44.3)341 (45.0)0.182BMI < 18.5 kg/m2a 175 (19.3)1,828 (19.1)2,003 (19.1)0.8419 (17.3)142 (20.5)151 (20.3)0.579Foreign52 (5.7)323 (3.4)375 (3.6)< 0.0014 (7.4)10 (1.4)14 (1.8)0.013Diabetes202 (22.3)2,222 (23.2)2,424 (23.1)0.5367 (13.0)203 (28.8)210 (27.7)0.012Cancer89 (9.8)878 (9.2)967 (9.2)0.5153 (5.6)62 (8.8)65 (8.6)0.613Initial TB-related symptoms0.1640.680No304 (33.6)2,998 (31.3)3,302 (31.5)14 (25.9)201 (28.6%)215 (28.4)Yes602 (66.4)6,578 (68.7)7,180 (68.5)40 (74.1)503 (71.4)543 (71.6)Prior TB history143 (15.8)1,143 (11.9)1,286 (12.3)0.00112 (22.2)90 (12.8)102 (13.5)0.050Initial disease severityb 0.2780.310Mild558 (61.6)5,721 (59.7)6,279 (59.9)21 (38.9)324 (46.0)345 (45.5)Severe348 (38.4)3,855 (40.3)4,203 (40.1)33 (41.1)380 (54.0)413 (54.5)Extra-pulmonary TB83 (9.2)966 (10.1)1,049 (10.0)0.3741 (1.9)59 (8.4)60 (7.9)0.059Treatment outcomesUnfavorable outcomesc 415 (45.8)3,542 (37.0)3,957 (37.8)< 0.00117 (31.5)126 (17.9)143 (18.9)0.014Failure1 (0.1)14 (0.1)15 (0.1)0.7731 (1.9)4 (0.6)5 (0.7)0.310Still-on-treatment178 (19.6)1,115 (11.6)1,293 (12.3)< 0.0017 (13.0)39 (5.5)46 (6.1)0.038Loss-to-follow-up19 (2.1)142 (1.5)161 (1.5)0.1511 (1.9)5 (0.7)6 (0.8)0.359Not evaluated137 (15.1)1,396 (14.6)1,533 (14.6)0.6585 (9.3)42 (6.0)47 (6.2)0.371All-cause mortality80 (8.8)875 (9.1)955 (9.1)0.7593 (5.6)36 (5.1)39 (5.1)0.753Values are presented as number (%).KTBC = Korean Tuberculosis Cohort, COSMOTB = Cohort Study of Pulmonary Tuberculosis, Hr-TB = isoniazid mono-resistant tuberculosis, DS-TB = drug-susceptible tuberculosis, BMI = body mass index, TB = tuberculosis.aThirty-four individuals in the KTBC and 14 individuals in the COSMOTB had missing data; bInitial disease severity: Mild [smear (−) & cavity (−)], Severe [smear (+) or cavity (+)]; cUnfavorable outcomes consist of death, failure, loss-to-follow-up, still-on-treatment, and not-evaluated. Baseline characteristics of patients with isoniazid mono-resistant tuberculosis and drug-susceptible tuberculosis enrolled from the KTBC registry and the COSMOTB Values are presented as number (%). KTBC = Korean Tuberculosis Cohort, COSMOTB = Cohort Study of Pulmonary Tuberculosis, Hr-TB = isoniazid mono-resistant tuberculosis, DS-TB = drug-susceptible tuberculosis, BMI = body mass index, TB = tuberculosis. aThirty-four individuals in the KTBC and 14 individuals in the COSMOTB had missing data; bInitial disease severity: Mild [smear (−) & cavity (−)], Severe [smear (+) or cavity (+)]; cUnfavorable outcomes consist of death, failure, loss-to-follow-up, still-on-treatment, and not-evaluated. Among 10,482 pulmonary TB patients from KTBC registry, 3,957 (37.8%) patients showed unfavorable outcomes. The proportion of KTBC patients with INH resistance, male sex, age older than 65 years, BMI lower than 18.5 kg/m2, foreign nationality, diabetes and cancer, initial TB-related symptoms, prior TB history and initially severe disease were significantly higher in unfavorable outcome group (Table 2). The univariable logistic regression analysis showed that unfavorable outcome was significantly associate with the INH resistance. The result was consistent after adjusting for confounders (adjusted odds ratio [aOR], 1.43; 95% confidence interval [CI], 1.24–1.65). Table 2Association between isoniazid resistance and clinical outcome among patients with pulmonary tuberculosis enrolled from the Korean Tuberculosis Cohort registryVariablesUnfavorable outcomes (n = 3,957)Favorable outcomes (n = 6,525)Total (N = 10,482)P valueCrude OR (95% CI)Adjusted OR (95% CI)Isoniazid resistance415 (10.5)491 (7.5)906 (8.6)< 0.0011.44 (1.26–1.65)1.43 (1.24–1.65)Sex, male2,560 (64.7)4,052 (62.1)6,612 (63.1)0.0081.12 (1.03–1.21)1.15 (1.05–1.25)Age ≥ 65 yr2,222 (56.2)2,997 (45.9)5,219 (49.8)< 0.0011.51 (1.39–1.63)1.53 (1.40–1.66)BMI < 18.5 kg/m2a 988 (25.1)1,015 (15.6)2,003 (19.2)< 0.0011.82 (1.65–2.01)1.75 (1.58–1.93)Foreign168 (4.2)207 (3.2)375 (3.6)0.0041.35 (1.10–1.67)1.68 (1.36–2.09)Diabetes1,019 (25.8)1,405 (21.5)2,424 (23.1)< 0.0011.26 (1.15–1.39)1.21 (1.10–1.33)Cancer448 (11.3)519 (8.0)967 (9.2)< 0.0011.48 (1.29–1.69)1.37 (1.19–1.58)Initial TB-related symptomsYes2,823 (71.3)4,357 (66.8)7,180 (68.5)< 0.0011.24 (1.14–1.35)1.13 (1.03–1.23)No1,134 (28.7)2,168 (33.2)3,302 (31.5)Prior TB history551 (13.9)735 (11.3)1,286 (12.3)< 0.0011.27 (1.13–1.43)1.23 (1.09–1.39)Initial disease severityb Severe1,785 (45.1)2,418 (37.1)4,203 (40.1)< 0.0011.40 (1.29–1.51)1.34 (1.23–1.45)Mild2,172 (54.9)4,107 (62.9)6,279 (59.9)Extra-pulmonary TB405 (10.2)644 (9.9)1,049 (10.0)0.5461.04 (0.91–1.19)Values are presented as number (%).Variables with P value < 0.20 in univariable analysis were selected for the multivariable logistic regression analysis.OR = odds ratio, CI = confidence interval, BMI = body mass index, TB = tuberculosis.aThirty-four individuals had missing data; bInitial disease severity: Mild [smear (−) & cavity (−)], Severe [smear (+) or cavity (+)]. Association between isoniazid resistance and clinical outcome among patients with pulmonary tuberculosis enrolled from the Korean Tuberculosis Cohort registry Values are presented as number (%). Variables with P value < 0.20 in univariable analysis were selected for the multivariable logistic regression analysis. OR = odds ratio, CI = confidence interval, BMI = body mass index, TB = tuberculosis. aThirty-four individuals had missing data; bInitial disease severity: Mild [smear (−) & cavity (−)], Severe [smear (+) or cavity (+)]. The result of the analysis on patients from COSMOTB database is shown in Table 3. There were 143 (18.9%) patients who had unfavorable outcomes, and the proportion of patients with INH resistance, older age, lower BMI, cancer, initial TB-related symptoms, prior TB history and initial severe disease were significantly higher in unfavorable outcome group. The univariable logistic regression analysis showed significant association between INH resistance and unfavorable outcomes, which was consistent after adjusting for confounders (aOR, 1.98; 95% CI, 1.02–3.85). Table 3Association between isoniazid resistance and clinical outcome among patients with pulmonary tuberculosis enrolled from the Cohort Study of Pulmonary TuberculosisVariablesUnfavorable outcomes (n = 143)Favorable outcomes (n = 615)Total (N = 758)P valueCrude OR (95% CI)Adjusted OR (95% CI)Isoniazid resistance17 (11.9)37 (6.0)54 (7.1)0.0142.11 (1.15–3.86)1.98 (1.02–3.85)Sex, male96 (67.1)385 (62.6)481 (63.5)0.3111.22 (0.83–1.97)1.31 (0.86–1.99)Age ≥ 65 yr84 (58.7)257 (41.8)341 (45.0)< 0.0011.98 (1.37–2.87)2.02 (1.34–3.04)BMI < 18.5 kg/m2a 44 (31.7)107 (17.7)151 (20.3)< 0.0012,16 (1.43–3.61)2.21 (1.43–3.43)Foreign3 (2.1)11 (1.8)14 (1.8)0.7351.18 (0.32–4.27)1.82 (0.46–7.30)Diabetes45 (31.5)165 (26.8)210 (27.7)0.2641.25 (0.84–1.86)1.26 (0.82–1.94)Cancer24 (16.8)41 (6.7)65 (8.6)< 0.0012.82 (1.64–4.85)2.84 (1.57–5.12)Initial TB-related symptomsYes114 (79.7)429 (69.8)543 (71.6)0.0171.70 (1.10–2.65)1.63 (1.02–2.61)No29 (20.3)186 (30.2)215 (28.4)Prior TB history29 (20.3)73 (11.9)102 (13.5)0.0081.89 (1.17–3.04)2.06 (1.22–3.47)Initial disease severityb Severe90 (62.9)323 (52.5)413 (54.5)0.0241.54 (1.06–2.23)1.55 (1.03–2.33)Mild53 (37.1)292 (47.5)345 (45.5)Extra-pulmonary TB14 (9.8)46 (7.5)60 (7.9)0.3571.34 (0.72–2.52)Values are presented as number (%).Variables with P value < 0.20 in univariable analysis of Korea Tuberculosis Cohort database were selected for the multivariable logistic regression analysis.OR = odds ratio, CI = confidence interval, BMI = body mass index, TB = tuberculosis.aFourteen individuals had missing data; bInitial disease severity: Mild [smear (−) & cavity (−)], Severe [smear (+) or cavity (+)]. Association between isoniazid resistance and clinical outcome among patients with pulmonary tuberculosis enrolled from the Cohort Study of Pulmonary Tuberculosis Values are presented as number (%). Variables with P value < 0.20 in univariable analysis of Korea Tuberculosis Cohort database were selected for the multivariable logistic regression analysis. OR = odds ratio, CI = confidence interval, BMI = body mass index, TB = tuberculosis. aFourteen individuals had missing data; bInitial disease severity: Mild [smear (−) & cavity (−)], Severe [smear (+) or cavity (+)]. For the sensitivity analysis on the association between INH resistance and the clinical outcomes, we redefined unfavorable outcomes by excluding the “not-evaluated” cases. The proportions of redefined unfavorable outcomes were significantly higher in the Hr-TB group compared to the DS-TB group, in both KTBC (30.7% vs. 22.4%, P = 0.020) and COSMOTB (22.2% vs. 11.9%, P = 0.028) databases. Multivariable analysis confirmed that INH resistance was significantly associated with poor treatment outcomes in the KTBC databases (aOR, 1.57; 95% CI, 1.34–1.84). The analysis result of COSMOTB database showed a consistent finding (aOR, 2.15; 95% CI, 1.02–4.55). Of 758 participants from COSMOTB, negative conversion of sputum culture test 2 months after anti-TB treatment was achieved in 670 (88.4%) participants. Their rates were not significantly different between the Hr-TB and DS-TB groups (87.0% vs. 88.5%, P = 0.747). The mean time to sputum negative culture conversion also was not significantly different between two groups (41.4 vs. 39.4 days, P = 0.695) (Fig. 2). Time to negative conversion of sputum culture among patients with and without isoniazid resistance, from the Cohort Study of Pulmonary Tuberculosis. The blue and the orange lines show the percentage of patients in Hr-TB and DS-TB group, respectively, who have not yet achieved sputum negative conversion over time. Hr-TB = isoniazid mono-resistant tuberculosis, DS-TB = drug-susceptible tuberculosis. Total of 81 participants from COSMOTB experienced serious adverse events (SAEs), not related to drugs, and 83 experienced serious adverse drug reactions (SADRs) (Table 4). The frequency of SADRs between Hr-TB and DS-TB showed significant difference, more frequent in the Hr-TB group. The percentage of patients who suffered SADRs within 1 year after the treatment initiation was significantly larger in the Hr-TB group. Incidence of SAEs in the hepatobiliary system was higher in the Hr-TB group, compared with that in the DS-TB group. Other factors, such as death and subtypes of SAE, showed no difference between groups. Table 4Serious adverse events in patients with isoniazid mono-resistant tuberculosis and drug-susceptible tuberculosisVariablesHr-TBDS-TBP valueNo. of patients54704Serious adverse eventsa Patients with at ≥ 1 event5 (9.3)76 (10.8)0.725No. of events691First event within 30 days after treatment initiation0 (0.0)26 (3.7)0.283First event within 1 yr after treatment initiation5 (9.3)61 (8.7)0.843Serious adverse drug reactionsb Patients with at ≥ 1 event12 (22.2)71 (10.1)< 0.001No. of events1385First event within 30 days after treatment initiation4 (7.4)34 (4.8)0.566First event within 1 yr after treatment initiation11 (20.4)70 (9.9)0.017DeathAny2 (3.7)19 (2.7)0.900Drug related0 (0.0)1 (0.1)0.929Serious adverse eventsEndocrine & metabolic0 (0.0)6 (0.9)0.641Neurologic & psychiatric1 (1.9)12 (1.7)0.856Cardiovascular0 (0.0)5 (0.7)0.690Gastrointestinal1 (1.9)22 (3.1)0.680Hepatobiliary7 (13)32 (4.5)0.032Musculoskeletal & connective tissue1 (1.9)2 (0.3)0.398Infection0 (0.0)1 (0.1)0.929Kidney & urinary tract0 (0.0)5 (0.7)0.690Neoplastic0 (0.0)6 (0.9)0.641Cutaneous & subcutaneous0 (0.0)12 (1.7)0.818Hematologic & lymphatics2 (3.7)16 (2.3)0.743Respiratory & mediastinal3 (5.6)28 (4.0)0.765Others2 (3.7)19 (2.7)0.363Values are presented as number (%).Hr-TB = isoniazid mono-resistant tuberculosis, DS-TB = drug-susceptible tuberculosis.aSerious adverse event refers to any unexpected adverse event that is life-threatening, require hospitalization or prolonged hospital days, or result in significant disability, that is not related to drug; bSerious adverse drug reaction refers to any unexpected adverse event that is life-threatening, require hospitalization or prolonged hospital days, or result in significant disability, that is related to drug. Serious adverse events in patients with isoniazid mono-resistant tuberculosis and drug-susceptible tuberculosis Values are presented as number (%). Hr-TB = isoniazid mono-resistant tuberculosis, DS-TB = drug-susceptible tuberculosis. aSerious adverse event refers to any unexpected adverse event that is life-threatening, require hospitalization or prolonged hospital days, or result in significant disability, that is not related to drug; bSerious adverse drug reaction refers to any unexpected adverse event that is life-threatening, require hospitalization or prolonged hospital days, or result in significant disability, that is related to drug. DISCUSSION This is the first prospective cohort study of large population evaluating the impact of INH resistance on the anti-TB treatment outcome. Using the large cohort registry of KTBC, we assessed the clinical outcomes of pulmonary Hr-TB patients with the objective of evaluating treatment outcomes and potential risk factors within the general population. To validate and reinforce these findings, we subsequently analyzed the COSMOTB dataset as an external validation dataset. Due to inherent differences in data collection methods and clinical data quality between the KTBC and COSMOTB databases, we analyzed the two datasets separately rather than conducting a joint analysis. In addition, we used the COSMOTB dataset to further compare impact of INH resistance on sputum culture conversion rate and the occurrence of SADRs. We found out that the rate of unfavorable outcomes was significantly higher in Hr-TB patients compared with that in DS-TB patients. INH resistance was significantly associated with the unfavorable outcome, which was consistent in the sensitivity analysis. Many studies that were conducted in other countries reported similar findings. Recent study by Araújo-Pereira et al.25 evaluated the clinical outcomes of Hr-TB patients in Brazil by using national database and concluded that INH resistance was independently related to unfavorable treatment outcomes. Karo et al.26 conducted a retrospective observational study on Hr-TB patients using European Surveillance System to evaluate treatment outcome. They adopted the term ‘still-on-treatment,’ which was also used in our study, for the analysis of the clinical outcomes, and found out that INH mono-resistance was associated with lower likelihood of treatment success. Comparable results have been documented by the studies conducted in Peru,27 Mexico,28 Georgia,29 and South Africa.30 In Korea, a high prevalence of elderly TB patients, who often have multiple comorbidities, contributes to the elevated TB mortality rate. Considering this epidemiological background, it is noteworthy that the association between INH resistance and mortality was not statistically significant in the current study. This finding contrasts with reports from Peru27 and Mexico,28 and the discrepancy may be attributed to several unique factors in Korea, including the lower severity of TB due to early detection through comprehensive surveillance, the prompt initiation of treatment upon diagnosis, and an effective TB management system supported by the robust national TB control program.21 These results underscore the critical importance of effective TB control at each stage—from TB diagnosis to treatment—in reducing the mortality from Hr-TB. The main cause of poor prognosis in the Hr-TB group was a higher proportion of prolonged treatment durations exceeding one year, as defined as still-on-treatment in our study. According to the WHO guidelines, Hr-TB treatment requires a minimum of 6-months after adding the Lfx, which can sometimes extend the total treatment duration to over 9 months. Timely treatment completion for RIF-susceptible TB is critical, which recommends completing treatment within one year, as highlighted by the Public Health England.31 The recent WHO update on TB treatment outcomes32 revised the definition of “treatment failed,” with prolonged treatment durations potentially reflecting clinical failure under these criteria. Identifying patients who are still on treatment at 12 months enables healthcare providers to assess potential barriers to completion and to implement targeted interventions. The high rate of still-on-treatment can be explained by several factors. First, prolonged treatment is often caused by discontinuation or modification of anti-TB medication due to adverse drug reactions. Indeed, the safety profile in our study revealed a significantly higher rate of SADRs in Hr-TB patients compared to DS-TB patients. The current WHO guidelines for Hr-TB treatment recommend the use of PZA for more than 2 months, which increases the risk of hepatotoxicity. Individualizing the duration of PZA administration could potentially mitigate the risk of ADRs and improve treatment outcomes.33 This was reflected in the guidelines of the United States and Europe, which recommend shortening the PZA duration when a later-generation fluoroquinolone is included in the Hr-TB regimen, particularly for patients with anticipated or experienced PZA toxicity, or those with non-cavitary, lower burden disease. Second, low compliance likely contributed to the extended treatment duration. Limited patient education about the disease and its management, combined with the stress from the prolonged treatment period, are the major causes of poor adherence. Clinicians should help Hr-TB patients understand the necessity of extended treatment durations and provide social and moral supports. In addition, further research for shorter treatment regimen for Hr-TB is needed. Lastly, the exclusion of INH from the treatment regimen may have delayed the treatment response, potentially leading to an extension of overall treatment duration. Although this study showed no difference in culture conversion rates, concerns remain about the reduced anti-TB efficacy due to the exclusion of INH from the treatment regimen, even with the substitution of Lfx. Such concerns, especially if the patient show delayed radiographic response, may lead physicians to extend the treatment duration as a precautionary measure. This study has some limitations. First, we used two prospective cohort for the analysis to compare the clinical characteristics in patients with Hr-TB and DS-TB, but the difference in group sizes was too large. The unbalanced number of the patients in the groups could have affected the analysis results, especially the study of COSMOTB. Additionally, the actual treatment regimens were not stratified based on the inclusion of fluoroquinolones, despite most Hr-TB patients received fluoroquinolone-based treatments. Individualized treatment adjustments, such as avoiding fluoroquinolones due to adverse drug reaction histories, were not accounted for. Lastly, classifying individuals with no sputum production at 2-month visit as culture-negative would have led to biased result. We considered these patients as having an improved disease status resulting from effective anti-TB treatment. Indeed, most of the patients with no sputum culture result at month 2 remained unable to produce sputum throughout the remaining treatment period yet achieved favorable outcome without disease recurrence. Therefore, we considered this potential bias to be minimal. In conclusion, INH resistance was significantly associated with unfavorable clinical outcomes among people with pulmonary TB. Further study is warranted to explore more effective treatment strategies for Hr-TB, highlighting the need for tailored strategies to improve treatment success and reduce its burden.